Shares of Webull Corp (NASDAQ:BULL) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results.

Webull reported second-quarter revenue of $198.83 million, beating estimates of $181.26 million, according to Benzinga Pro. The brokerage platform company posted second-quarter adjusted earnings of five cents per share, beating estimates of 3 cents per share.

Webull shares jumped 13.7% to $9.82 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Gainers

• Reitar Logtech Holdings Ltd (NASDAQ:RITR) gained 179% to $0.21 in pre-market trading after declining more than 5% on Wednesday.
• BTC Digital Ltd (NASDAQ:BTCT) rose 105.6% to $1.72 in pre-market trading after jumping 75% on Wednesday.
• Loop Industries Inc (NASDAQ:LOOP) rose 79% to $1.11 in pre-market trading. The company disclosed in a Form8 filing that it granted ELITe non-transferable, perpetual, exclusive, royalty-bearing license to depolymerization technology and related intellectual property rights o build and operate licensed manufacturing facilities in India.
• Beam Global (NASDAQ:BEEM) rose 39.6% to $1.69 in pre-market trading after the company reported better-than-expected quarterly financial results.
• Evaxion A/S (NASDAQ:EVAX) rose 25.5% to $3.95 in pre-market trading. Evaxion, recently, expanded and refocused R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
• Megan Holdings Ltd (NASDAQ:MGN) rose 54.4% to $0.16 in pre-market trading.
• BioVie Inc (NASDAQ:BIVI) rose 13.3% to $1.52 in pre-market trading after jumping 39% on Wednesday. BioVie recently posted a fourth-quarter loss of 70 cents per share.
• Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) gained 11.2% to $29.19 in pre-market trading. Ultragenyx announced the US FDA approval of GENGLYCOS gene therapy, the first-ever FDA-Approved treatment designed to treat the underlying cause of glycogen storage disease Type Ia (GSDIa).
• Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares gained 10% to $4.20 in pre-market trading. Zentalis Pharmaceuticals recently announced the pricing of its $80.5 million proposed public offering of 23 million shares at $3.50 per share.

Losers

• Tenon Medical Inc (NASDAQ:TNON) tumbled 30.7% to $7.92 in pre-market trading. Tenon Medical shares jumped 109% on Wednesday after the company received a notice of allowance for a U.S. Patent Titled “Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints.”
• Onfolio Holdings Inc (NASDAQ:ONFO) fell 29.4% to $1.67 in pre-market trading after the company reported second-quarter 2026 results showing lower revenue and a wider loss.
• OSR Health Inc (NASDAQ:OSRH) declined 28.1% to $0.27 in pre-market trading. OSR Health said it plans to request panel hearing after receiving Nasdaq delisting determination.
• Surgepays Inc (NASDAQ:SURG) fell 23.6% to $0.19 in pre-market trading. SurgePays, on Friday, reported better-than-expected second-quarter financial results.
• Matinas BioPharma Holdings Inc (NYSE:MTNB) fell 22.1% to $0.19 in pre-market trading after gaining 18% on Wednesday.
• Autozi Internet Technology (Global) Ltd (NASDAQ:AZI) fell 19.3% to $1.34 in pre-market trading. Autozi Internet Technology shares jumped 44% on Wednesday after the company announced that it has received an aggregate investment of $30 million from multiple investors.
• Yunji Inc (NASDAQ:YJ) fell 20.2% to $3.39 in pre-market trading after jumping 144% on Wednesday.
• Moderna Inc (NASDAQ:MRNA) fell 12.4% to $153.01 in pre-market trading. Moderna shares jumped 177% on Wednesday after the company and Merck announced topline results from the Phase 3 INTerpath-001 trial met its primary and a key secondary endpoint.
• Wolfspeed Inc (NYSE:WOLF) fell 12% to $25.60 in pre-market trading after the company reported mixed fourth-quarter financial results.
• Coty Inc (NYSE:COTY) fell 7.7% to $2.80 in pre-market trading after the company reported mixed fourth-quarter financial results and issued first-quarter adjusted EPS guidance below estimates. The company disclosed that the Gucci Beauty license exit will result in a step-down in FY28 sales and profit.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.